Letters
Incretins and pancreatic cancer
Involving patients in drug licensing decisions
BMJ 2013; 347 doi: https://doi.org/10.1136/bmj.f4329 (Published 16 July 2013) Cite this as: BMJ 2013;347:f4329- Nicky Britten, professor of applied health care research1,
- Sarah Denford, associate research fellow1,
- Ken Stein, director of peninsula technology assessment group (PenTAG)1
- 1University of Exeter Medical School, Institute of Health Research, Exeter EX2 4SG, UK
- N.Britten{at}exeter.ac.uk
Gale’s editorial about the adverse consequences of incretins concludes that: “The problem lies in a system that subordinates the public interest to commercial secrecy.”1 Another problem is that the system does not regard patients, or the public, as legitimate stakeholders whose judgments could or should contribute to licensing decisions.
The National Institute for Health Research Collaboration for Leadership in Applied Health Care …
Log in
Log in using your username and password
Log in through your institution
Subscribe from £173 *
Subscribe and get access to all BMJ articles, and much more.
* For online subscription
Access this article for 1 day for:
£38 / $45 / €42 (excludes VAT)
You can download a PDF version for your personal record.